Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 5
Submit an article Journal homepage
848
Views
194
CrossRef citations to date
0
Altmetric
Review

The role of data mining in pharmacovigilance

Manfred Hauben Takeda Global Research and Development, Inc., Department of Pharmacoepidemiology and Outcomes Research, Lincolnshire, Illinois, USA. [email protected]
,
David Madigan Takeda Global Research and Development, Inc., Department of Pharmacoepidemiology and Outcomes Research, Lincolnshire, Illinois, USA. [email protected]
,
Charles M Gerrits Takeda Global Research and Development, Inc., Department of Pharmacoepidemiology and Outcomes Research, Lincolnshire, Illinois, USA. [email protected]
,
Louisa Walsh Takeda Global Research and Development, Inc., Department of Pharmacoepidemiology and Outcomes Research, Lincolnshire, Illinois, USA. [email protected]
&
Eugene P Van Puijenbroek Takeda Global Research and Development, Inc., Department of Pharmacoepidemiology and Outcomes Research, Lincolnshire, Illinois, USA. [email protected]
Pages 929-948 | Published online: 07 Sep 2005

Bibliography

  • MEYBOOM RH, EGBERTS AC, EDWARDS IR et al: Principles of signal detection in pharmacovigilance. Drug Sal: (1997) 16(6):355–365.
  • ••Eloquent discussion of the nuancesof signal detection and evaluation.
  • HAND D, BLUNT G, KELLY M, ADAMS N: Data mining for fun and profit. Stat. Science (2000) 15(2):111–131.
  • GOODWIN L, VANDYNE M, LIN S, TALBERT S: Data mining issues and opportunities for building nursing knowledge. I Biomed Inform. (2003) 36(4-5):379–388.
  • LI X, RAO S, WANG Y, GONG B: Gene mining: a novel and powerful ensemble decision approach to hunting for disease genes using microarray expression profiling. Nucleic Acids Res. (2004) 32(9):2685–2694.
  • PERNER P: Image mining: issues, framework, a generic tool and its application to medical image diagnosis. Journal Engineering applications of artificial intelligence (2002) 15(3):193–203.
  • HAUBEN M, REICH J: Communication of findings in pharmacovigilance: use of term 'signal' and the need for precision in its use. Eur.Phannacol (2005) 61(5-6):479–480.
  • BATEMAN DN, SANDERS GL, RAWLINS MD: Attitudes to adverse drug reaction reporting in the Northern Region. BE I Clin. Phannacol. (1992) 34(5):421–426.
  • BELTON KJ: Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur. I Clin. Phannacol. (1997) 52(6):423–427.
  • BELTON KJ, LEWIS SC, PAYNE S, RAWLINS MD, WOOD SM: Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br. J. Clin. Phannacol (1995) 39(3):223–226.
  • COSENTINO M, LEONI 0, BANFI F, LECCHINI S, FRIGO G: Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Phannacol Res. (1997) 35(2):85–88.
  • DE BRUIN ML, VAN PUIJENBROEK EP, EGBERTS AC, HOES AW, LEUFKENS HG: Non-sedating antihistamine drugs and cardiac arrhythmias - biased risk estimates from spontaneous reporting systems? Br. .1. Phannacol (2002) 53(4):370–374.
  • ELAND IA, BELTON KJ, VAN GROOTHEEST AC et al: Attitudinal survey of voluntary reporting of adverse drug reactions. BE J. Clin. Phannacol (1999) 48(4):623–627.
  • WILLIAMS D, FEELY J: Underreporting of adverse drug reactions: attitudes of fish doctors. kJ. Med. Sci. (1999) 168(4):257–261.
  • BEGAUD B, MORIDE Y, TUBERT-BITTER P, CHASLERIE A, HARAMBURU F: False-positives in spontaneous reporting: should we worry about them? Br. J. Clin. Phannacol (1994) 38(5):401–404.
  • •Describes a method based on the Poisson distribution for computing the maximum number of reports of an ADR that could be expected to be reported coincidentally, and relates this to the concept of DMEs.
  • TRONTELL A: Expecting the unexpected-drug safety, pharmacovigilance, and the prepared mind. N Engl. I Med. (2004) 351(101385–1387.
  • ••An excellent description by an expertat the FDA, of signal detection as a comprehensive process using multiple approaches and techniques.
  • BATE A, LINDQUIST M, EDWARDS IR et al.: A Bayesian neural network method for adverse drug reaction signal generation. Eurj Clin. Phannacol (1998) 54(4):315–321.
  • ••A seminal paper describing the BCPNN.
  • EGBERTS AC, MEYBOOM RH, VAN PUIJENBROEK EP: Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Sal: (2002) 25(6):453–458.
  • EVANS SJ, WALLER PC, DAVIS S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidenhol Drug Sal (2001) 10(6):483–486.
  • ••Describes the applicationof PRR at the MHRA.
  • FRAM D, ALMENOFF J, DUMOUCHEL W: Empirical Bayesian data mining for discovering patterns in post-marketing drug safety. (9th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, August 24–27, 2003, Washington), (2003) p359–368.
  • HAUBEN M: A brief primer on automated signal detection Quantitative methods in pharmacovigilance: focus on signal detection. Ann. Phannacother. (2003) 37(7-8):1117–1123.
  • SZARFMAN A, MACHADO SG, O'NEILL RT: Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Sal: (2002) 25(6):381–392.
  • HAUBEN M, REICH L: Safety related drug-labelling changes: findings from two data mining algorithms. Drug Sal: (2004) 27(10):735–744.
  • HAUBEN M: Trimethoprim-induced hyperkalaemia - lessons in data mining. BE Pharmacol (2004) 58(3):338–339.
  • MADIGAN D: Discussion of `Bayesian data mining in large frequency tables' by Bill DuMouchel. Am. Stat. (1999) 53:198–200.
  • DUMOUCHEL W: Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. (1999) 53(3):170–190.
  • ••A seminal paper describing the empirical Bayesian approach to signal detection in pharmacovigilance.
  • MOSELEY J, HEELEY E, EKINS-DAUKES S, EVANS S: Preliminary comparison of 2 signal detection methodologies in the UK regulatory spontaneous ADR data base. [Abstract]. Drug Sal: (2004) 27(12):950–951.
  • VAN PUIJENBROEK EP, EGBERTS AC, HEERDINK ER, LEUFKENS HG: Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. I Clin. PharmacoL (2000) 56(9-10):733–738.
  • VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br. J. Clin. Pharmacol (1999) 47(6):689–693.
  • VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? Pharmacoepidemiol Drug Sal: 0001) 10(2):135–142.
  • NEYMAN J: On the application of probability theory to agricultural experiments. Essay on principles. Section 9, translated in Statistical Science, (with discussion). Stat. Science (1990) 5(4):465–480.
  • RUBIN D: Causal inference using potential outcomes: design, modeling, decisions. JASA (2005) 100(469):322–331.
  • CART WRIGHT NE: Nature's Capacities and Their Measurements Cartwright N (ed.) Oxford University Press, Oxford, (1994):
  • ROSENBAUM P, RUBIN D: The central role of the propensity score in observational studies for causal effects. Biometrika (1983) 70(1):41–55.
  • CORNFIELD J, HAENSZEL W, HAMMOND EEA: Smoking and lung cancer: recent evidence and a discussion of some questions. ./. Natl. Cancer Inst. (1959) 22(1):173–203.
  • LINDQUIST M, STAHL M, BATE A et al: A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Sal (2000) 23(6):533–542.
  • SPIGSET 0, HAGG S, BATE A: Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharmacol (2003) 18(3):157–161.
  • SANZ EJ, DE-LAS-CUEVAS C, KIURU A, BATE A, EDWARDS R: Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet (2005) 365(9458):482–487.
  • COULTER DM, BATE A, MEYBOOM RH, LINDQUIST M, EDWARDS IR: Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BAII(2001) 322(7296):1207–1209.
  • BATE A, LINDQUIST M, ORRE R et al: Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur. j Clin. Pharmacol (2002) 58(7):483–490.
  • ••Provides cogent and relevant demonstrations and discussion, including graphical data visualisation tools, of the BCPNN, using real-world examples.
  • VAN PUIJENBROEK EP, EGBERTS AC, MEYBOOM RH, LEUFKENS HG: Different risks for NSAID-induced anaphylaxis. Ann. Pharmacother. (2002) 36(1):24–29.
  • VAN PUIJENBROEK EP, BATE A, LEUFKENS HG et al.: A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Sal (2002) 11(1):3–10.
  • O'NEILL RT, SZARFMAN A: Some US Food and Drug Administration perspectives on data mining for pediatric safety assessment. Curr. Thar. Res. (2001) 62(9):650–663.
  • SZARFMAN A, TONNING JM, DORAISWAMY PM, MACHADO SG, O'NEILL RT: Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy (2004) 24(9):1099–1104.
  • BANKS D, WOO E, BURWEN D et al: Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug. Sal (2005) Published Online: 13 Jun 2005
  • PURCELL P, BARTY S: Statistical techniques for signal generation: the Australian experience. Drug Sal: (2002) 25(6):415–421.
  • GOULD AL: Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Sal (2003) 12(7):559–574.
  • ••A comprehensive, well-written andInsightful discussion of both theoretical concepts and issues related to the practical deployment of DMAs.
  • HAUBEN M, REICH L: Drug-induced pancreatitis: lessons in data mining. BE J. Clin. Pharmacol (2004) 58(5):560–562.
  • ••Describes points to consider whenusing DMAs.
  • HAUBEN M, REICH L: A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation. BE J. Clin. Pharmacol (2004) 58(6):675–676.
  • HAUBEN M, REICH L: Data mining, drug safety, and molecular pharmacology: potential for collaboration. Ann. Pharmacother. (2004) 38(12):2174–2175.
  • HAUBEN M, REICH L: Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an 'old' drug. Mov. Disord. (2005) 20(3):387–388.
  • HAUBEN M, REICH L: Case reports of dobutamine-induced myoclonia in severe renal failure: potential of emerging pharmacovigilancetechnologies. NephroL Dial. Transplant (2005) 20(2):471–472.
  • HAUBEN M, REICH L: Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation. Infect. Control Hosp. Epideiniol (2005) 26(4):391–394.
  • HAUBEN M, REICH L, CHUNG S: Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur.Pharinacol (2004) 60(10):747–750.
  • HAUBEN M, REICH L: Potential utility of data-mining algorithms for early detection of potentially fatal/ disabling adverse drug reactions: A retrospective evaluation. J. Clin. Pharmacol (2005) 45(4):378–384.
  • HAUBEN M: Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Pharinacother. (2004) 24(9):1122–1129.
  • HAUBEN M: Early postmarketing drug safety surveillance: data mining points to consider. Ann. Pharmacother. (2004) 38(10):1625–1630.
  • ALMENOFF JS, DUMOUCHEL W, KINDMAN LA, YANG X, FRAM D: Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepideiniol Drug Sal: (2003) 12(6):517–521.
  • ALMENOFF J, DUMOUCHEL W, KINDMAN L, YANG X, FRAM D: Letter to the Editor-Re: Almenoff et al., Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting'. Pharinacoepideiniol Drug Sal: (2004) 13(3):111.
  • ROUX ET-B, P.,THESSARD F,FOURRIER A,BEGAUD A,EVANS S.: Automatic signal detection methods evaluation on a simulated data base. Workshop 20th International Conference on Pharmacoepideiniology & Therapeutic Risk Management, Bordeaux, France, 2004.
  • ROUX E, TUBERT-BITTER P, THIESSARD F: Evaluation of data mining methods in pharmacovigilance using simulated datasets. 20th International Conference on Pharmacoepidemiology Therapeutic Risk Management, Bordeaux, France, 2004.
  • KUBOTA K, KOIDE D, HIRAI T: Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Sal: (2004) 13(6):387–394.
  • DE BRUIN ML, PETTERSSON M, MEYBOOM RH, HOES AW, LEUFKENS HG: Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. (2005) 26(6):590–597.
  • HARVEY JT, TURVILLE C, BARTY SM: Data mining of Australian adverse drug reactions database: a comparison of Bayesian and other statistical indicators. Intl. Tram Op. Research (2004) 11:419–433.
  • HAUBEN M, PATADIA V, GERRITS C, WALSH L, REICH L: Data mining in pharmacovigilance: the need for a balanced perspective. Drug Sal (2005) 28 (in Press).
  • STAHL M, LINDQUIST M, EDWARDS IR et al.: Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Sal (2004) 13(6):355–363.
  • FINNEY DJ: The detection of adverse reactions to therapeutic drugs. Stat. Med. (1982) 1(2):153–161.
  • NOREN G, ORRE R, BATE A: A hit-miss model for duplicate detection in the WHO drug safety database. Proceedings of the 11th ACM SICKDD international conference on knowledge discovery and data mining, August 2005, Chicago, USA.
  • GOGOLAK VV: The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Pharmacoepidemiol Drug Sal (2003) 12(3):249–252.
  • ALTUNDAG 0, CELIK I, KARS A: Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann. Pharmacother. (2001) 35(5):641–642.
  • YEE C, KLINCEWICS S, KNIGHT J, THOMAS A, WILSON R: Practical consideration in developing an automated signaling program within a pharmacovigilance department. Drug Inf J. (2004) 38(3):293.
  • •Describes how one pharmaceutical company incorporates DMAs in their current pharmacovigilance practices.
  • HAUBEN M, REICH L: Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Pharmacother. (2004) 24(9):1122–1129.
  • PURCELL PM: Data mining in pharmacovigilance Int. I Pharm. Med. (2003) 17(2):63–64.
  • BROWN EG: Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Sal: (2002) 25(6):445–452.
  • BROWN EG: Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Sal: (2003) 26(3):145–158.
  • BROWN EG: Using MedDRA: implications for risk management. Drug Sal: (2004) 27(8):591–602.
  • HAND D: Technical report, Department of Mathematics, Imperial College London.
  • STROM BL: Evaluation of suspected adverse drug reactions. JAMA (2005) 293(11):1324–1325.
  • ALMENOFF JS, DUMOUCHEL W, KINDMAN LA et al: Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Sal: (2003) 12(6):517–521.

Websites

  • http://www.fda.gov/cder/aers/default.htm FDA website Adverse event reporting system (2005).
  • http://medicines.mhra.gov.uldourworld monitorsafequalmed/yellowcard/yellow cardscheme.htm MHRA website Yellow card scheme (2005).
  • http://www.who-umc.org/ The Uppsala Monitoring Centre (2005).
  • http://statrutgers.eduRmadigan/BBR Bayesian Binary Regression software (2005).
  • http://www.ailab.si/idamap/idamap 192003/ Roux.pdf Spontaneous reporting system modelling for data mining methods evaluation in pharmacovigilance. Conference on intelligent data analysis in medicine and pharmacology. October 2003, Protaras, Cyprus. (2005).
  • http://www.outcome.com/new_home/ images/pharmacovig3_05.pdf Guidance for industry: Good pharmacovigilance practices and pharmacoepidemiologic assessment (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.